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MODULATION

OF

ATP-SENSITIVE

POTASSIUM

CHANNEL

ACTIVITY

BY

ATP-BINDING

CASSETTE TRANSPORTERS: A MODEL FOR CHANNEL REGULATION
Tong-Yi Yao and Marie E. Egan.

Department of Pediatrics, Yale University, School of Medicine, New

Haven, CT.
The aim of this study was to characterize the relationship between ATP-Binding Cassette (ABC)
transporters and heterologous ion channels.

Our hypothesis

was that regulation of ATP-sensitive

potassium channel activity by ABC transporters is through direct interactions dependent upon motifs
specific to this superfamily.

If the hypothesis is valid, it suggests that certain ABC transporters may be

able to interact with numerous ion channels. Furthermore, if direct coupling of specific domains or residues
on the ABC transporter and channel protein are necessary, mutations in either protein would disrupt this
interaction, diminishing the ABC transporters ability to modulate channel activity.
Using two-electrode voltage clamping, this study examined two ABC transporters, the cystic
fibrosis transmembrane conductance regulator (CFTR) and the pancreatic beta cell high-affinity sulfonylurea
receptor (SUR1), and their interactions with “associated” inwardly-rectifying ATP-sensitive potassium
channels, the renal potassium channels (ROMK 1/Kirl.la and ROMK2/Kirl.lb) and the pancreatic
potassium channel (BIR/Kir6.2).

Expression of either ROMK1 (Kir 1.1a) or ROMK2 (Kiri.lb) alone in

Xenopus oocytes resulted in barium-sensitive potassium currents with minimal to moderate sulfonylurea
(glibenclamide) sensitivity.

Coexpression of either CFTR or SUR1

enhanced the sensitivity of the potassium currents to sulfonylurea.

with ROMK2 (Kiri.lb) greatly

In contrast, neither the expression of

CFTR or SUR1 with ROMK1 (Kiri.la) enhanced the effects of glibenclamide on potassium currents.
fact, the expression of CFTR with ROMK1 (Kiri.la) decreased the glibenclamide effect.

In

These data

suggest that the interaction of ABC transporters with ion channels is dependent upon characteristics of both
subunits.
Lastly, we examined the clinical impact of disrupting the interactions between ABC transporters
and ATP-sensitive potassium channels in a case of familial hyperinsulinemic hypoglycemia of infancy
(PHHI).

In accordance with our above findings, coexpression of SUR1

with a BIR (Kir6.2) mutant

'
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identified in an infant with PHHI failed to produce a potassium current, demonstrating that a nonfunctional
BIR (Kir6.2) mutant resulted in a potassium channel that was nonfunctional.
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1.

1-1.

Introduction

ATP-Binding Cassette Transporter Superfamily

1-1.1. The Typical ABC Transporter
The ATP-binding cassette (ABC) transporters are a superfamily of over 100
transmembrane proteins characterized by a highly conserved ATP-binding cassette, or
nucleotide binding fold (NBF) (Higgins, 1992; Higgins, 1995). In general, their structure
consists of four core domains—two transmembrane domains and two nucleotide-binding
domains (Figure 1).

In prokaryotes, the four domains exist more commonly as separate

polypeptides while in eukaryotes they tend to exist as fused multidomain complexes.
Whether

expressed

as

separate

polypeptides

or

as

a

multidomain

protein,

the

transmembrane domains appear to associate with and anchor the two nucleotide-binding
domains. Several bacterial transporters appear to have a highly conserved short sequence
on a cytoplasmic loop of the transmembrane domain which may interact with the
nucleotide-binding domains.

Members of this superfamily function as selective active

transporters or channels. ABC transporters may either export or import substrate; none, at
present, demonstrate bidirectional transport. Substrates range from simple inorganic ions,
sugars, and amino acids to more complex polysaccharides and proteins.
While the ABC transporter superfamily is defined by the basic four domain
complex described above, there is limited sequence conservation between different proteins
in the family. The highest degree of sequence identity is found in the nucleotide-binding
domains. No experimental data (NMR, crystallographic, microscopic) detailing the exact
structure of ABC transporters is presently available. Computer-generated predictions based
upon the amino acid sequence suggest that each transmembrane domain consists of multiple
alpha-helical membrane-spanning segments with the N- and C- termini are usually present
on the cytoplasmic side. Exceptions such as the sulfonylurea receptor whose N-terminus is
extracellular do exist. Although a typical ABC transporter has six segments, significant

'
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variation in the number of alpha-helical membrane-spanning segments present in each
transmembrane domain occurs.

1 -1.1.1. Role of the Transmembrane Domains
The transmembrane domains are believed to form the path for substrate transport
and determine substrate specificity (Higgins, 1992; Higgins, 1995).

As the proteins are

involved in the transport of highly diverse substrates and as the amino acid residues
responsible for specificity need not be adjacent on the primary sequence, the amino acid
sequences of the transmembrane domains exhibit great variability when comparing between
different proteins. However, sequence similarities that do exist between transporters do
not necessarily translate into similarities in substrate

specificity.

When the two

transmembrane domains present in each individual ABC transporter are compared there is
generally greater sequence identity present.

In ABC transporters with only a single

transmembrane domain, it may function as a

homodimer.

Greater sequence identity is

found between the two distinct transmembrane domains of a single ABC transporter
suggesting they may function together as a pseudodimer.

1-1.1.2. Role of the Nucleotide-Binding Domains
The highly hydrophilic nucleotide-binding domains reside on the cytosolic side of
the membrane where their nucleotide binding folds interact with cytosolic nucleotides
(Higgins, 1992; Higgins, 1995).

These domains typically couple the energy of ATP

hydrolysis to the transport of substrates across the

membrane

perhaps

through

conformational changes affecting the transmembrane domains. There is a high degree of
sequence conservation in these domains between ABC transporters with up to 30-50%
sequence identity depending on the proteins compared.

Greater sequence identity is

generally present between the two nucleotide-binding domains of a single transporter. This
sequence identity includes the Walker A and Walker B motifs which are responsible for

3

interacting with the phosphates of nucleotides and associated with many other nucleotide¬
binding proteins. The presence of both nucleotide-binding domains is necessary for the
function of the protein; however, the two nucleotide-binding domains are not necessarily
functionally equivalent.

For example, in P-glycoprotein, mutations in either domain

impacts adversely on transport activity. However, in cystic fibrosis many mutations in the
first (or N-terminal) nucleotide-binding domain of CFTR result in a disease state but a
mutation in the C-terminal nucleotide-binding domain does not appear to inhibit CFTR
function (Welsh and Smith, 1993).

1-1.2. ABC Transporters and Disease
ABC transporters are now known to be involved in a variety of human diseases
(Table 1) ranging from cystic fibrosis (CF) and persistent hyperinsulinemic hypoglycemia
of infancy (PHHI), which are our focus in these studies, to other recessively inherited
diseases such as X-linked adrenoleukodystrophy, Zellweger syndrome, and Stargardt
macular dystrophy as well as multifactorial diseases such as noninsulin-dependent diabetes.
In addition, ABC transporters affect the course of human

disease by

conferring

chemotherapeutic drug resistance to cancer cells as well as antibiotic resistance to a variety
of infectious microorganisms.

1-1.3. ABC Transporters as Channel Regulators
Studies have suggested that ABC transporters may interact with heterologous ion
channel proteins regulating their activity (Higgins, 1995). This regulatory function may be
as an extension of their intrinsic transporter or channel functions or a result of either direct
or indirect interactions with these other channel proteins. Understanding how they function
as channel regulators may give insight into the pathophysiology of the diseases associated
with ABC transporter dysfunction and may provide new targets for treatment of the disease
process.

'
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1-1.3.1. Mechanisms of Channel Regulation
Four major models of regulation above the level of gene expression have been
proposed to explain the mechanism by which ABC transporters may regulate other channel
proteins (Figure 2) (Higgins, 1995).

The first model assumes that a substrate (X)

transported by the ABC protein acts as regulatory molecule to modulate channel activity in
an autocrine fashion. In this model, the ABC protein’s regulation of another channel is a
consequence of its intrinsic transporter function.

The second model proposes direct

interactions between the ABC transporter and the channel protein as the basis of modulation
of channel activity. These could involve protein-protein interactions or the formation of an
ABC transporter-channel protein complex.

The third and fourth models are of indirect

interactions not associated with the ABC protein’s transporter function; one looks upon the
ABC transporter as a facilitator of increased insertion of channel proteins into the
membrane while the other model postulates the coupling of the ABC transporter with
intermediate protein molecules, possibly cytoskeletal components, thereby effecting the
channel protein.
Our studies focus upon the direct model of channel regulation. Direct interactions
appear to explain how CFTR and SUR1 function as channel regulators. More specifically,
the regulation of channel activity appears to be dependent upon the presence of specific
motifs of ABC transporters, such as the NBFs (McNicholas et al., 1997).

1-1.3.2. Multidrug Resistance Gene Product P-glvcoprotein
P-glycoprotein

is

responsible

for

the

multidrug

resistance

of cancers

to

chemotherapeutic drugs. P-gp functions as an active exporter of hydrophobic compounds
including chemotherapeutic drugs. When overexpressed in cancer cells P-gp confers upon
them multidrug resistance by reducing the cytoplasmic concentrations and cytotoxicity of
the chemotherapeutic drugs. The energy to pump the drugs out of the cell is derived from

4
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ATP hydrolysis. P-gp expression is also associated with increased volume-activated Cl
channel currents suggesting that it may be a multifunctional protein with an additional
physiological function as a regulator of epithelial cell volume (Gill et al., 1992; Valverde et
ah, 1992). The volume-activated Cl channel appears to be sensitive to osmotic gradients.
P-gp appears to affect the channel activation through altering this sensitivity as well as
imposing a dependency on protein kinase C.

1-1.4. Promiscuity of ABC Transporters
Studies have suggested that ABC transporters may be able to substitute for other
members of the family in their interactions with heterologous proteins (Ammala et ah,
1996). Whether this ability to substitute for other members of the family is a consequence
of similarities in motifs allowing for equivalent direct coupling of ABC transporters with
channel proteins is unclear.

Another possibility is that ABC transporters capable of

exporting or importing similar substrates may substitute for one another.

For example,

such a relationship was found to exist between two ABC transporters, P-gp and STE6
which is responsible for exporting

a-factor mating peptide in yeast (Raymond et ah,

1992). When the mouse mdr3 gene which produces P-pg was expressed in a yeast cell
with an ste6 deletion, the cell regained its ability to export a-factor.

In this study, a

mutation known to affect the activity of P-gp was then introduced into the mdr3 gene.
Coexpression of this mutant with the STE6 deficient yeast cell did not restore function.
Studies done coexpressing SUR1 with inwardly rectifying potassium channels (Kirl.la and
Kjr6.1) other than BIR (Kir6.2) suggest that it is able to interact with multiple Kjr channels
and confer sulfonylurea sensitivity (Ammala et ah, 1996).

1-2.

Cystic Fibrosis Transmembrane Conductance Regulator
The cystic fibrosis transmembrane conductance regulator (CFTR) is a somewhat

atypical ABC transporter. Unlike the vast majority of ABC transporters, CFTR functions
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as a chloride channel not as a transporter and possesses a five domain structure—two
transmembrane domains, two nucleotide-binding domains, and an additional regulatory Rdomain which appears to block the channel pore (Figure 3) (Fuller and Benos, 1992;
Riordan, 1993; Tsui, 1995; Davis et al., 1996).

Phosphorylation of this R-domain by a

cyclic AMP-dependent protein kinase A (PKA) is required for channel activation.
Maintenance of channel activity requires the continued presence of ATP at the NBFs.

In

addition, there appear to be other phosphorylation sites which may modulate channel
kinetics and activity as well.

1-2.1. Role in Regulation of Respiratory Secretions
Normal function of CFTR appears important for effective mucociliary clearance, the
mechanism by which inhaled foreign matter are removed from the lungs.

Respiratory

secretions are critical in the maintenance of mucociliary clearance (Welsh, 1988). The two
components of the system are the cilia of the epithelial cells and the respiratory fluids. The
respiratory fluids can be conceived as a bilayer with a discontinuous mucus layer, or gel
phase, overlying a periciliary fluid layer, or sol phase, in which the cilia are immersed.
The mucus layer serves to trap inhaled particles whereas the periciliary fluid provides a
watery medium in which the cilia can beat freely. The tips of the cilia are in contact with
the mucus facilitating its movement along with the foreign matter towards the larynx.
A number of features of the airway epithelium are critical for the maintenance of
electrolyte and water transport necessary to ensure the appropriate quantity and composition
of the periciliary fluid as well as the quality of the mucus. The airway epithelial cells are
polar with distinct apical and basolateral surfaces. The ciliated apical membrane facing the
lumen and the basolateral membrane facing the interstitial space differ in the types of
receptors, transporters, and channels present.

The two cell surfaces are further

differentiated by the presence of tight junctions joining the epithelial cells along their apical
surfaces producing a continuous barrier between the luminal and interstitial spaces.

This

'
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barrier serves as a semipermeable membrane allowing regulated solute and water movement
with net secretion or absorption. Two pathways of movement across the airway epithelium
exist—a paracellular pathway between cells at the tight junctions and a cellular pathway
through the epithelial cells themselves.
The interplay between chloride secretion and sodium absorption determines whether
fluid is secreted or absorbed by the epithelium, respectively (Welsh, 1988). Whether one
or the other process predominates is dependent upon the neurohumoral environment and
the anatomical region of the airway.
paracellular pathways.

Both, however, are dependent upon cellular and

Chloride secretion “begins” with chloride entry across the

basolateral membrane coupled to sodium entry. This is an electrically neutral cotransport
process in which chloride moves against its electrochemical gradient while sodium moves
down its electrochemical gradient.

Whether the cotransport process involves a Na7Cl

cotransporter or a Na7K72Cl" cotransporter is dependent upon cell type. The chloride then
moves passively across the apical membrane down it electrochemical gradient through
chloride channels. Some of the apical chloride channels involved are the cystic fibrosis
transmembrane regulator (CFTR) chloride channel, the outwardly rectifying chloride
channel (ORCC), and the calcium-activated chloride channel.

The basolateral Na7K+

pump, or Na+,K+-ATPase, is responsible for maintaining the low intracellular sodium
concentrations and negative intracellular voltage necessary for this chloride secretion. The
intracellular potassium accumulated through the Na+,K+-ATPase as well as the Na7K72Cl'
cotransporter passively leaves the cell through a basolateral potassium channel.

This

basolateral potassium channel also serves to maintain a negative intracellular voltage
conductive to chloride leaving the cell at the apical membrane.

The net result of the

depolarizing transport of chloride across the apical membrane and the hyperpolarizing
transport of potassium across the basolateral membrane is a transepithelial voltage which
drives the paracellular flow of sodium from the interstitial space to the lumen (Figure 4),

Sodium absorption “begins” with sodium entry across the apical membrane through
sodium channels down its electrochemical gradient.

The Na+,K+-ATPase then pumps

sodium against its electrochemical gradient across the basolateral membrane.
This balance of secretion and absorption impacts upon mucociliary clearance
through two mechanisms—the hydration of the mucus layer and the depth of the periciliary
fluid layer. Airway mucus is produced and secreted primarily by the submucosal glands;
however, additional secretory products of goblet cells, ciliated cells, and Clara cells also
contribute to its composition.

As fluid secretion decreases when chloride secretion

decreases or sodium absorption increases, the mucus and periciliary layers become
dehydrated making the mucus more viscous and the periciliary layer too shallow for
effective ciliary beating.

Likewise, fluid result in a periciliary layer which is too deep

preventing the cilia tips from contacting with and moving the mucus layer.

1-2.2. Role in Cystic Fibrosis
Cystic Fibrosis (CF) is a common genetic disease affecting the Caucasian
population with a frequency of approximately one in 2500 live births.

This autosomal

recessive disease affects multiple organ systems including the respiratory, gastrointestinal,
and reproductive systems.

The underlying defect in CF is in the gene encoding CFTR

located on chromosome 7 (Riordan et al., 1989; Rommens et al., 1989).

Although the

gene was not identified until 1989 by Riordan et ah, studies by Quinton and Knowles and
Boucher during the early 1980s had already demonstrated the primary defect as a decrease
in chloride permeability.
infection

in

the

The characteristic clinical findings of mucus plugging and

airways,

pancreatic

insufficiency,

and

elevated

sweat

chloride

concentrations are a result of this alteration of chloride permeability in secretory epithelial
cells in the airways, exocrine pancreas, and sweat glands. Recently, Smith et ah postulated
that this alteration in chloride and sodium permeability may lead to changes in airway
surface fluid which, in turn, may alter the natural defenses of the lung by inactivating salt-
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sensitive peptides, such as defensins (Smith et al., 1996).

Currently, the progressive

airway disease—decreased mucociliary clearance, mucus plugging, bronchiectasis, and
ultimately respiratory failure—is the major cause of morbidity and mortality in CF patients
(Fuller and Benos, 1992; Riordan, 1993; Tsui, 1995; Davis et al., 1996).
Mutations resulting in the loss or reduction of CFTR’s chloride conductance can be
classified into four categories dependent on where they impact on the “pathway” of CFTR
production and function following insertion into the cell membrane (Welsh and Smith,
1993). This “pathway” can be conceptually divided into four areas: protein production,
protein processing/trafficking, channel regulation/activation, and chloride conduction
(Table 2).

Defects in channel regulation/activation can also be conceptualized as defects

within the nucleotide binding domains, specifically the NBF, as they are intimately
involved in channel regulation/activation. Likewise, defects in chloride conduction appear
to be localized to the transmembrane domains which are postulated to form the channel
pore.

The most common mutation is a single amino acid deletion of phenylalanine at

position

508

(AF508).

The

AF508

mutation

results

in

defective

protein

processing/trafficking. The AF508 protein appears to be incorrectly folded and therefore
not trafficked to the Golgi apparatus where it would otherwise be fully glycosylated and
subsequently transported to the cell membrane for insertion.

1-2.3. CFTR as Regulator of Heterologous Channel Activity
CF-affected cells exhibit a number of ion transport abnormalities—increased
sodium absorption, abnormal regulation of outwardly rectifying chloride channels
(ORCCs), and increased calcium-activated chloride channel activity—which can not be
explained solely by CFTR’s function as a chloride channel. CFTR appears to be a cAMPdependent regulator of amiloride-sensitive epithelial sodium channels (ENaC) (Stutts et al.,
1995; Mall et al., 1996). The mechanism of this interaction while presumed to be direct,
however, is unclear.

CFTR regulation of ORCCs, which are present in the apical

10

membranes of airway epithelium, may involve the release of ATP to the extracellular
surface (Gabriel et al., 1993; Jovov et al., 1995; Schwiebert et ah, 1995).

Whether the

ATP is transported by CFTR, by an associated channel regulated by CFTR, or by another
mechanism is unclear. What is evident is that in CF-affected cells the normal regulation of
ORCCs by PKA and ATP is defective and that expression of wild type CFTR in these
same cells corrects the defect (Egan et ah, 1992).

The increase in calcium-activated

chloride channel activity appears to be a result of up-regulation (Grubb et ah, 1994).
Correction of the calcium-activated chloride channel activity and ENaC activity when CFaffected cells are transfected with CFTR supports the notion that CFTR is critical to the
regulation of these channels.

1-2.3.1. CFTR and Potassium Channels
There is also evidence that CFTR can modify KATP channel activity.

The ROMK

family of apically-located renal KATP channels is a subgroup of the inwardly rectifying
potassium (Kir) channel superfamily (Hebert and Ko, 1994; Zhou et ah, 1994; Boim et ah,
1995). Kjr channels maintain the membrane potential (Em) of numerous excitable and nonexcitable cells near the potassium reversal potential (EK) (Fakler and Ruppersburg, 1996;
Ackerman and Clapham, 1997).

KATP channels within the apical membrane of distal

nephron segments of the kidney play a major role in potassium homeostasis.

Multiple

isoforms of ROMK have been identified. ROMK2 (Kiri.lb), an alternate splice isoform
with 19 fewer amino acid residues present on the N-terminus than ROMK1 (Kiri.la),
maintains many of the characteristics of native renal KATP channels; however, it lacks the
same sensitivity to sulfonylureas such as glibenclamide. Coexpression of CFTR, which is
present in the nephron, with ROMK2 (Kiri.lb) appears to confer this glibenclamide
sensitivity to the KATP channel (McNicholas et al., 1996).

As this effect was not found to

be dependent upon PKA and ATP, active transport by CFTR does not appear to be
necessary, suggesting a direct interaction between CFTR and ROMK.

A recent study

demonstrated CFTR as localizing to the apical membrane of the cortical collecting duct
where ROMK2 (Kiri.lb) has previously been found (Todd-tura et al., 1996).

In light of

these studies, a role for CFTR in the regulation of ROMK channel activity appears
possible.
This ability of CFTR to regulate KATP channel activity is also present in another
member of the ABC transporter superfamily, SUR1.

1-3.

Sulfonylurea Receptor
The complementary DNA for SUR1 was first cloned in 1995 by Aguilar-Bryan et

al. classifying it as a member of the ABC transporter family because it showed significant
sequence similarities to other members of the superfamily such as P-gp and CFTR
(Aguilar-Bryan et al., 1995).
consensus

sequences

characteristics.

were

Two nucleotide binding folds with Walker A and B
identified.

SUR1,

however,

has

unique

structural

Although a multidomain protein like many other eukaryotic ABC

transporters, it possesses nine and four segment transmembrane domains alternating with
the two nucleotide-binding domains.

Its N-terminus is also located extracellularly.

SURl’s role in pancreatic beta cell KATP channel activity was initially unclear because, as a
member of the ABC transporter superfamily, it could function either as the potassium
transporter itself or as the regulator of a separate potassium channel subunit. Expression of
SUR1 alone resulted in no channel activity, suggesting that coupling with BIR (Kir6.2)
was necessary for a functional KATP channel.

1-3.1. Role in Regulation of Glucose Homeostasis
The pancreatic beta cell ATP-sensitive potassium (KATP) channel is postulated to be
a complex of two subunits, SUR1 and BIR (Kir6.2) (Figure 5) (Philipson and Steiner,
1995; Inagaki et al., 1995). SUR1 appears to serve as the regulator of channel activity
while BIR (Kir6.2) forms the channel pore. Studies in which expression of either SUR1
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or BIR (Kir6.2) alone did not yield K+ currents above the endogenous levels of the cell
system support the theory that they act as a functional unit (Aguilar-Bryan and Bryan,
1996; Gribble et al., 1997). SUR1 was originally of clinical interest because of the use of
sulfonylureas as oral hypoglycemics to stimulate insulin secretion from pancreatic beta cells
in the treatment of non-insulin dependent diabetes mellitus (NIDDM).
In physiologic regulation of glucose homeostasis, the KATP current (IKAXP) sets the
resting membrane potential for the pancreatic beta cell (Aguilar-Bryan and Bryan, 1996).
Increases in the glucose concentration translate into an increase in the cytosolic ATP to
ADP ratio which closes the KATP channel and blocks the outflow of potassium.

The

subsequent depolarization of the membrane results in the activation of voltage-dependent Ltype calcium channels. The calcium influx triggers exocytosis and insulin release (Figure
6). Sulfonylureas such as glibenclamide bring about insulin release through inhibition of
the Katp channel.

1-3.2. Role in Persistent Hyperinsulinemic Hypoglycemia of Infancy (PHHI)
Persistent hyperinsulinemic hypoglycemia of infancy (PHHI) is a rare autosomal
recessive disorder of glucose metabolism characterized by recurrent episodes of profound
hypoglycemia associated with abnormal regulation of insulin secretion (Aguilar-Bryan and
Bryan, 1996; Permutt et al., 1996). These episodes of severe hypoglycemia can present in
the early newborn period or as late as several months of age.

In all cases, whether the

plasma insulin levels are high normal or grossly elevated, there is inappropriately high
levels of insulin during hypoglycemia. In order to avoid hypoglycemia, patients require
parenteral glucose, often in high doses. Current treatment strategies include pharmacologic
interventions such as diazoxide or a somatostatin analog. Octreotide, as well as surgical
options such as partial pancreatectomy for refractory hyperinsulinism.

Although the

disease was described as early as 1953 by McQuarrie and has also been referred to as
familial hyperinsulinism and pancreatic nesidioblastosis, the molecular basis was not
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elucidated until 1995 when Aguilar-Bryan et al. cloned the gene and Thomas et al. reported
the first findings of mutations in SUR1 in families with PHHI (Aguilar-Bryan et al., 1995;
Thomas et al., 1995). PHHI has an incidence of one in 50,000 live births in the western
European population. In populations such as the Saudi Arabians where there is a high
percentage of consanguineous matings, the incidence is much higher, approximately one in
2500 live births. The existence of such families with PHHI facilitated mapping the gene to
chromosome 11 p 15.1 by linkage analysis. Both SUR1 and BIR (Kir6.2) are clustered on
chromosome 11 p 15.1 with the BIR (Kir6.2) gene immediately 3’ of the SUR1 gene.
Recent studies have attributed patient cases to mutations in the first and second nucleotide¬
binding fold regions of SUR1 as well as to mutations in BIR (Kir6.2) (Thomas et al.,
1996).

In some cases these mutations led to truncated proteins while in others they

disrupted RNA processing.

Both nucleotide-binding domains, however, appear to be

necessary for nonnal channel activity. It appears that mutations in either SUR1 or BIR
(Kir6.2) could result in continuous membrane depolarization and subsequent continuous
secretion of insulin.
Mutations in SUR1 have also been implicated in NIDDM suggesting that the BIR
(Kir6.2)-SUR1 complex plays a pivotal role in the regulation of insulin secretion and
maintenance of glucose homeostasis (Nestorowicz, et al., 1996).

1-3.3. SUR1 as Regulator of Heterologous Channel Activity
SUR1 has been demonstrated to interact with numerous KATP channels other than
BIR (Kir6.2), affecting their regulation by sulfonylureas (Ammala et al., 1996).

These

studies have suggested that interactions between ABC transporters and certain ion channels
may be promiscuous.
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2.

Statement of Purpose

Our hypothesis is that ABC transporters are multifunctional proteins that act not
only as active transporters or channels, but also as regulators of heterologous channels.
More specifically, we hypothesize that ABC transporters regulate heterologous channel
activity via direct interactions dependent upon motifs specific to ABC transporters. If direct
coupling of specific domains or residues on the ABC transporter and channel protein is
necessary, mutations in either protein would disrupt this interaction diminishing the ABC
transporters ability to modulate channel activity.

To examine the possibility of ABC

transporters substituting for one another in their interactions with heterologous channel
proteins, studies were done looking at possible relationships between ABC transporters
(CFTR and SUR1)
BIR/Kir6.2).

and KATP channels

(ROMKl/Kirl.la,

ROMK2/Kirl.lb,

and

In addition, preliminary studies examining the interactions between SUR1

(wild type) and BIR/Kir6.2 (wild type and mutant) were performed.

Together, these

experiments will help determine the structure-function relationship responsible for the
interaction between ABC transporters and channel proteins and elucidate what regions of
the ABC transporters are necessary for channel regulation.
All two-electrode voltage clamp studies were performed upon mRNA-injected
Xenopus oocytes. More specifically, the following questions were addressed in this study:

1) Do mutations in specific domains of CFTR impair its ability to interact with the channel
protein ROMK2 (Kiri.lb) thus altering the channel activity or glibenclamide
sensitivity of the coexpressed peptides?
2) Can SUR1 substitute for CFTR in the CFTR/ROMK interaction?
3) Do alterations in ROMK affect its ability to interact with CFTR thus altering the channel
activity or glibenclamide sensitivity of the coexpressed peptides?
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4) Do mutations in specific domains of either SUR1 or BIR (Kir6.2) impair their ability to
interact thus altering the glibenclamide sensitivity of the coexpressed peptides?

H
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3.

3-1.

Methods

Xenopus Oocyte Expression System

The Xenopus laevis oocyte expression system was first introduced in 1971 by Gurdon
as a means to study the control of gene expression (Gurdon et al., 1971).

In 1982, Miledi

et al. demonstrated that injection of exogenous mRNA into the cytoplasm resulted in
expression of ion channels and receptors. As stage V and VI oocytes possess adequate
protein translation and modification machinery, it has proven to be a reliable expression
system for the study of ion channels and transporters (Sherman-Gold, 1993). The oocytes
are readily harvested through partial ovariectomy through a small incision in the frog’s
abdominal wall. With an adequate recovery period, frogs can be operated upon multiple
times.
Oocytes develop in a six stage process from I to VI.

Stage V and VI oocytes are

approximately 1-1.2 mm and possess two distinct poles—a darker-colored animal pole and
a lighter, cream-colored vegetal pole. The vitelline membrane, a glycoprotein matrix which
provides structural support in maintaining the oocytes’ spherical shape, envelops each
individual oocyte. An additional layer of follicular cells surrounds the vitelline membrane.
These follicular cells are electrically coupled to one another and to the oocyte by gap
junctions. As these follicular cells can interfere with recordings, they are removed prior to
RNA injection and voltage or patch clamping. The collection of oocytes, follicular cells,
connective tissue, and blood vessels constitutes an ovarian lobe.

3-1.1. Harvesting of Xenopus Oocytes
A single frog (Nasco, Xenopus Express, or Xenopus One) was selected for oocyte
harvest through partial ovariectomy. Care was taken to select a frog whose prior surgical
incisions have been allowed to heal at least 3 to 4 weeks. The frog was anesthetized in a
0.17% tricaine (3-aminobenzoic acid ethyl ester, methane sulfonate salt, Sigma) bath pH
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7.4 at room temperature for approximately 10-15 minutes until it was unresponsive when
held in the supine position. The frog was then placed in the supine position on a layer of
Saran Wrap over a tray of ice.

These measures were taken to ensure clean conditions,

reduce risk of frostbite, and maintain moisture levels in the frog skin.

Sterile gloves were

used throughout the procedure. All surgical instruments were cleaned with 70% isopropyl
alcohol prior to each use and periodically autoclaved as well.
contamination as much as possible.

Care was taken to avoid

A small horizontal incision approximately 1 cm wide

was made in the abdomen wall, lateral to the midline. Three to four ovarian lobes were
gently removed from the abdominal cavity using forceps and scissors. These lobes were
placed in Ca2+-free ND96 solution. The wound was closed in two layers. The muscle and
fascial layers were closed together with 5-0 chromic gut (Ethicon). The skin was closed
with 6-0 ethilon (Ethicon). The frog was then placed into a clean individual tank for a few
hours to recover from the anesthesia and surgery prior to return to the general tank.

3-1.2. Preparation. Selection, and RNA Injection of Xenopus Oocytes
The ovarian lobes were gently dissected into smaller sections using forceps.

In

order to separate the oocytes from the connective tissue, blood vessels, and follicular cells
which together form the lobe, they were treated with collagenase A (Sigma or Boehringer
Mannheim) at a concentration of 2 mg/ml of Ca2+-free ND96 and gently agitated for 1 to
1.5 hours at room temperature. Any remaining follicular cells were manually removed with
forceps. After incubation in collagenase, the oocytes were washed with Ca2+-free ND96 to
stop the digestion process and then washed with the more isotonic Ca2+-plus ND96.
Oocytes were stored in Ca2+-plus ND96 supplemented with 450pM gentamicin (Gibco) and
2.5mM sodium pyruvate (Boehringer Mannheim) in a 18°C incubator. An alternate oocyte
media based upon half-strength Leibovitz L-15 Medium (Gibco BRL) and 5mM Hepes
supplemented with penicillin/streptomycin (500U/ml of media) and 50pg/ml (500pM)
gentamicin was used as well.

18

Oocytes were selected on the basis of maturity (stage V and VI) and uniformity in
the color of the animal and vegetal poles with a clear boundary between the two. Care was
taken to examine the oocytes daily and to remove any cells with areas of decoloration, a
speckled appearance, or outpouching of the membranes—all signs of a dying cell.

The

storage media was also changed every other day.
Care was taken throughout the injection protocol to minimize contamination by
RNases.

Gloves were worn at all times when handling the mRNA.

Disposable

micropipettes (Drummond Microcaps, 64mm length, 6 pi) were pulled using a pipette
puller (Narishige). The end of the tip was clipped under the microscope for an opening
diameter of approximately 5pm.

The mRNA solution consisted of either a single type of

mRNA or two types mixed together prior to injection. Concentrations of the mRNAs were
0.03 or O.lpg/pl

for ROMK1 (Kiri.la), 0.03 or O.lpg/pl

for ROMK2 (Kiri.lb),

0.5pg/pl for CFTR, 0.5 to 0.8pg/pl for SUR1, 0.4 to 0.6pg/pl for BIR (Kir6.2), and
0.5pg/pl for A9 (a BIR/Kir6.2 mutant). For injection, the mRNA solution was transferred
to a RNase-free surface.

The injection pipette was attached to a hand-driven, coarse

manipulator (MK1 Manipulator, Singer Instruments) which was connected to a pneumatic
injector (Inject+Matic, Geneve).

The droplet of mRNA solution was aspirated into the

pipette as quickly as possible to avoid excessive evaporation of the microliter volumes.
Pressure and time of injection were adjusted to ensure that approximately 50nl aliquots
were injected into each oocyte. Exogenous mRNA was injected preferably into the vegetal
pole as the voltage clamp microelectrodes were inserted into the animal pole during
experiments.

3-2.

Molecular Biology

3-2.1. Bacterial Cell Transformation and Plasmid Purification
Subcloning efficiency DH-5a or DM1 competent Escherichia coli cells were used
for bacterial cell transformation.

Approximately 500ng of plasmid DNA was added to
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lOOjal of competent cells in a chilled microcentrifuge tube and incubated on ice for 30
minutes. The mixture was heat shocked for 45 seconds at 37°C before being placed back
on ice for 2 minutes. 0.9ml of Luria-Bertani (LB) media without antibiotics (ampicillin)
was added to the microcentrifuge tube and then the E. coli/plasmid DNA mixture was
grown on a shaker for 1 hour to overnight at 37°C.

A series of dilutions of the

transformation growup was plated on LB-ampicillin (100 pg/ml) agar plates and then
incubated at 37°C overnight. Ampicillin was used to apply selection pressure ensuring that
only daughter cells containing the plasmid of interest remain.

A single bacterial colony

from the LB-ampicillin plates was used for growup. Depending on the plasmid purification
kit being used (Qiagen Midi-prep, 5 Prime-^3 Prime BIGprep, or 5 Prime—>3 Prime
PERFECTprep), the single colony was inoculated in 5-60 ml of LB buffer plus ampicillin
(100 pg/ml) and shaken overnight at 37°C.
Terrific Broth (TB) can be used as well.

Alternate “richer” growth media such as

Plasmid purification was performed per the

protocols provided in the various kits.
The basic principle of plasmid purification is lysis of bacterial cells followed by
purification and isolation of supercoiled plasmid DNA.

The amount of culture volume

processed in each sample is dependent upon the cell density.

If the volume is too large

there may be inefficient cell lysis, overload of the binding column, and a high lysate
viscosity. Care must be taken to mix the lysate thoroughly but gently to avoid shearing of
the bacterial genomic DNA whose fragments may contaminate the plasmid DNA.

The

lysate is applied to a resin column where the plasmid DNA is selectively bound.

The

column is washed with buffers to remove RNA and protein contaminants.

The plasmid

DNA is then eluted from the column, desalted, concentrated, washed, and finally
resuspended in RNase-free H20. The plasmid DNA is stored at -20°C.

'
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3-2.2. Linearization of cDNA
Basic principles of setting up a restriction reaction include:

1) choosing an

appropriate restriction enzyme, 2) determining the concentration of the enzyme, 3)
determining the minimum amount of enzyme required for effective linearization, 4)
determining the concentration of the plasmid DNA, 5) deciding upon the amount of DNA to
be linearized, 6) deciding upon the desired excess of enzyme, and 7) calculating the amount
of buffer and other solutions needed for optimal action of the specific restriction enzyme.
The restriction reaction is incubated for 1.5 to 2 hours or overnight at 37°C.

After an

appropriate period of incubation, proteinase K and sodium dodecyl sulfate (SDS) are added
to halt the restriction reaction, digest the remaining restriction enzyme, and eliminate RNase
contamination. Care is taken from this point to remain RNase-free. The plasmid DNA is
extracted with a 25:24:1 (vol.) phenol:chloroform:isoamyl alcohol mixture.

The phenol

serves to denature proteins in the nucleic acid solution. Subsequent chloroform extractions
serve to remove residual phenol from the aqueous phase containing the linearized DNA.
Together, these extractions also remove residual SDS which may interfere with in vitro
transcription reactions. Ammonium acetate and ethanol are added to precipitate the nucleic
acid and to reduce coprecipitation of unincorporated nucleotides. The precipitate is washed
in ethanol to remove residual salts and ethylenediamine-tetraacetic acid (EDTA) which may
later interfere with bacteriophage RNA polymerases.

Finally, it is microcentrifuged to

pellet the DNA and allowed to dry prior to resuspension of the linearized DNA in RNasefree dH20 and stored at -20°C.
Human SUR1 subcloned into PCR3.1 or Bluescript M13 was provided by Dr.
Pamela Thomas (University of Michigan, Ann Arbor). SUR1 was linearized using Xba I
restriction enzyme (New England BioLabs) for cleavage at the carboxy-terminal (3’) end.
Human BIR (Kir6.2) subcloned into PCR2.1 was provided by Dr. Pamela Thomas
(University of Michigan, Ann Arbor). BIR (Kir6.2) was linearized using Spe I restriction
enzyme (New England BioLabs).
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Human CFTR subcloned into pBQ4.7 was provided by Drs. William B. Guggino
and Erik M. Schwiebert (Johns Hopkins University, Baltimore and University of Alabama
Birmingham, Birmingham). CFTR was linearized using EcoR V restriction enzyme (New
England BioLabs).
Human ROMK2 (Kiri.lb) subcloned into pSportl was provided by Drs. Gerhard
Giebisch (Yale University, New Haven) and Steven C. Hebert (Vanderbilt University,
Nashville).

ROMK2 (Kiri.lb) was linearized using Not I restriction enzyme (New

England BioLabs).

3-2.3. In Vitro Transcription of Capped mRNA
In vitro transcription was performed using the Ambion MEGAscript or mMessage

mMachine kits to produce capped mRNA for Xenopus oocyte injection purposes. Capping
of mRNA allows for more efficient translation.

Each kit includes the appropriate

bacteriophage RNA polymerase (SP6, T7, or T3) as well as transcription buffer, enzyme
mix, ribonucleotide solutions, DNase, transcription stop mix, and lithium chloride
precipitation solution.
The general principles of in vitro transcription involve the assembly of a
transcription reaction which consists of linearized template DNA, ribonucleotides, cap
analog, RNA polymerase, and transcription buffer. This transcription reaction is incubated
at 37°C for 1 to 6 hours depending on the length of the transcript and the transcription kit
being used. DNase 1 is added to stop transcription and degrade the template DNA.

The

mRNA is then precipitated by lithium chloride and washed by ethanol to remove
unincorporated nucleotides.

An alternative method is phenol/chloroform extraction

followed by precipitation with ammonium acetate and isopropyl alcohol, a process which
may be more effective in removal of proteins.

Both methods end with centrifugation to

pellet the mRNA, careful removal of the supernatant, and resuspension of the mRNA in
RNase-free dH2Q. The mRNA was stored at -80°C.

%
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3-2.4. Verification of cDNA and mRNA by Gel Electrophoresis
Care was taken to verify that the appropriate plasmid DNA had been produced
during the bacterial growup and subsequent plasmid purification process by 1% agarose gel
electrophoresis.

Prior to extraction and purification of the linearized cDNA,

gel

electrophoresis was repeated to confirm successful linearization of the cDNA in the
restriction reaction. As the mRNA produced by in vitro transcription is sensitive to RNases
present in the environment, the quality of the mRNA is confirmed by gel electrophoresis
prior to injection into oocytes.

3-3.

Two-Electrode Voltage Clamp Technique

3-3.1. Theory
Voltage clamp studies are based upon the principle of setting the membrane voltage
and measuring the transmembrane current require to maintain that voltage (Sherman-Gold,
1993). By clamping the voltage, the capacitive spike/transient is effectively limited to the
brief time required to charge the membrane prior to changing the membrane to the set
voltage.

In doing so, the current effectively becomes proportional to the membrane

conductance which is determined by the number of open channels.
The intracellular microelectrodes used in two-electrode voltage clamping consist of
a AgCl-coated Ag wire placed within a solution-filled glass micropipette.
electrode resistance concentrated KC1 solution can be used.

To reduce

While such a solution also

allows more accurate measurement of resting potential, it has the disadvantage of
potentially altering the normal ion concentrations within the cell as a result of the fluid
connection which exists between the electrode and the cell interior.

Smaller pipette tip

diameters would minimize such mixing; however, the concomitant increase in the resistance
of the pipette becomes the limiting factor as it impacts on current passing ability and noise.
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Selection of the glass used for the intracellular microelectrodes is dependent upon
the magnitude of currents to be measured, the degree of “acceptable” noise, and the need to
generate a tight seal.

Thickness of the walls determines the degree of electrical noise

generated and the bluntness at the tip.

Other properties of the glass to consider are the

temperature required to soften the glass and the noise that it will generate. For the purposes
of two-electrode voltage clamping, sharper tips on the standard intracellular microelectrodes
are required in order to penetrate the cell membrane. For patch clamp experiments, glass
selection is more critical in order to achieve gigaohm seals.

Our micropipettes were pulled

in a vertical multiple stage Narishige pipette puller.
Voltage clamping oocytes poses two unique challenges due to the size of the cell
and its relative efficiency in expressing injected mRNA. In stage V and VI oocytes, the
surface area, assuming an ideal spherical shape and not taking into account invagination of
the membrane, is on the order of 106 pm2.

As capacitance is proportional to area, the

current necessary to charge up the membrane prior to changing the membrane potential is
significant and consequently the time to charge the membrane is longer.

In addition, the

large currents which may result from efficient channel protein expression and insertion into
the cell membrane may pose problems in controlling the voltage. To address the problem
of such a large membrane capacitance, lower resistance electrodes can be utilized.
Appropriate shielding of the electrodes to reduce capacitive coupling also improves the
speed at which voltage changes can be achieved.

3-3.2. Channel Recording and Analysis
Data was

acquired through the GeneClamp 500 (Axon Instruments) with

conversion of the continuous analog data into digital format through the Clampex program
within the pCLAMP6 suite (Axon Instruments). The Clampex program set the membrane
at various holding potentials while simultaneously recording the transmembrane current.
At specified time points—one minute intervals for our experiments—a trial was completed
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and the data acquired was saved to a data file. Data was viewed on a monitor (Gateway
2000 Vivitron 1776).

Recordings were exported to computer (Gateway 2000 P5-166)

through the Clampfit program and then converted to spreadsheet format in Microsoft Excel
for analysis.

3-4.

Protocol

3-4,1. Rationale for Use of Potassium Channel Blockers and Openers
A number of pharmacologic agents were used in the experiments including
sulfonylureas,

barium,

diazoxide,

and

sodium

azide.

The

sulfonylureas,

oral

hypoglycemics used in the treatment of NIDDM, are of interest in our studies because of
the high sensitivity of SUR1 to these compounds as well as their interactions with CFTR,
another member of the ABC transporter family.

A variety of different sulfonylureas

(glibenclamide, tolbutamide, etc.) are currently available. They are lipophilic molecules
and appear to be effective in blocking KATP current from either side of the membrane,
perhaps as a result of diffusion across the membrane. The other potassium channel blocker
used in our experiments is barium. Barium has been demonstrated to block a variety of
potassium channels (voltage-gated, inwardly rectifying, ATP-sensitive). This suggests that
there may be similarity between the pore regions of these potassium channels.
Diazoxide, a benzothiadiazine structurally similar to the sulfonylureas, is an
effective opener of the potassium channel in pancreatic beta cells. It produces membrane
repolarization and consequently inhibition of insulin secretion.

It also appears to be

effective from either side of the membrane and dependent upon both ATP and Mg2+ for its
action.
Sodium

The exact mechanism by which diazoxide activates KATP channels is unclear.
azide is a metabolic inhibitor of mitochondrial electron transport protein

cytochrome

and the F,/F0 ATPase. Sodium azide brings about a decrease in intracellular

ATP levels which presumably allows for an activation of the BIR (Kir6.2)-SUR1 channel
complex and subsequent potassium currents.
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3-4.2. Protocol for ROMK-Coiniected Oocytes
Two-electrode voltage clamp experiments measuring whole-cell currents and
response to sulfonylureas were performed on Xenopus oocytes injected with ROMK1
(Kiri.la) alone, ROMK2 (Kiri.lb) alone, ROMK1 (Kiri.la) plus CFTR or SUR1, and
ROMK2 (Kir 1.1b) plus CFTR or SURl. Experiments were performed on days 2-6 post¬
injection to ensure adequate time for channel protein expression.

Experiments were

conducted at room temperature, 20-22°C. All oocytes were maintained in 0.01 K+ or 0.1
K+ bath solution prior to the start of each experiment. For each experiment, micropipettes
(Kimax-51, Kimble Products) with typical resistances of 0.5-1.5

MO were used.

Resistances were checked prior to each experiment and no set of micropipettes was used
for more than three consecutive experiments.
For experiments where ROMK1 (Kiri.la) or ROMK2 (Kiri.lb) where expressed
alone, oocytes were preincubated in 0.01 K+ bath solution for 10 minutes. Initial baseline
current readings were obtained in this bath solution. Following impalement of the oocyte
with both microelectrodes, the resting membrane potential was measured prior to clamping
the membrane at a specified holding potential (typically -65mV). The experimental protocol
consisted of current-voltage measurements (a trial) recorded at 60 second intervals in
various bath solutions. Each trial consisted of as series of 20ms test pulses starting at lOOmV increasing in 20mV increments up to a final voltage of +40mV or -1-lOOmV. The
protocol began with a 5 minute equilibration period in 0.01 K+ bath solution followed by a
14 minute test of sulfonylurea (glibenclamide) sensitivity. After assessing the response to
glibenclamide, barium chloride (2mM) was then added to the bath solution for 2 minutes to
determine the extent to which the current was dependent upon potassium movement.

A

final 5 minute recovery period in 0.01 K+ bath solution concluded the experiment.
For experiments in ROMK1 (Kirl.la)-CFTR and ROMK2 (Kirl.lb)-CFTR
coexpressed oocytes, the above protocol was also used.
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For experiments in ROMK1-SUR and ROMK2 (Kirl.lb)-SUR coexpressed
oocytes, the protocol was modified as follows.

During set-up of the voltage clamp, the

oocytes were transferred out of the Ca2+-plus ND96 storage media into 0.1 K+ or 0.5 K+
bath solution for approximately 3 to 5 minutes to allow the oocyte to re-equilibrate in the
lower potassium solution. The protocol consisted of 5 minutes in 0.1 K+ or 0.5 K+ bath
solution followed by 5 to 7 minutes in lOOpM or 250pM glibenclamide, 5 minutes
recovery period in 0.1 K+ or 0.5 K+ bath solution, 2 to 3 minutes in 2mM barium chloride,
and a final wash in 0.1 K+ or 0.5 K+ bath solution.
Control experiments in uninjected oocytes were subject to the same protocols as
described above.

3-4.3. Protocol for BIR-Coinjected Oocytes
Two-electrode voltage clamp experiments measuring whole-cell currents and
response to sulfonylureas were performed on Xenopus oocytes injected with BIR (Kir6.2)
alone, SUR1 alone, BIR (Kir6.2) plus SUR1, and A9 (BIR/Kir6.2 mutant) plus SUR1.
Conditions for experiments were as above (Section 3-4.2).
Experiments were initially performed on oocytes injected with BIR (Kir6.2) alone.
BIR (Kir6.2) is postulated to be the pore subunit of the pancreatic beta cell KATP channel.
To assess the level of channel activity present when expressed alone experiments were
done exposing the oocyte first to standard ND96 (2mM KC1) bath solution then to High K+
(90mM KC1) bath solution.

As we did not expect variations in the intracellular ATP

concentration to result in BIR (Kir6.2) activation, no preliminary experiments with sodium
azide were done.
Next, to confirm that SUR1 expressed alone would not result in potassium current
and to assess if SUR1 could couple with any endogenous oocyte channels, experiments
were done exposing the oocyte first to standard ND96 (2mM KC1) bath solution then to
High K+ (90mM KC1) bath solution. As a member of the ABC transporter superfamily,
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SUR1 is responsive to changes in intracellular ATP concentrations. To assess if sodium
azide metabolic inhibition of the oocyte would cause channel activation, experiments were
done exposing the oocyte for 5 minutes to High K+ bath solution then 15 minutes to 3mM
sodium azide.
Lastly, we examined oocytes coexpressing BIR (Kir6.2)-SUR1.

The protocol for

these coinjected oocytes was 7 minutes in High K+ bath solution followed by 16 to 17
minutes in High K+ bath solution plus 340pM diazoxide and 5mM sodium azide.
For oocytes coinjected with SUR1 and the BIR (Kir6.2) mutant A9, the protocol
used was 3 minutes in High K+ bath solution followed by 15 minutes in High K+ bath
solution plus 340pM diazoxide and 5mM sodium azide. To assess if duration of exposure
to diazoxide and sodium azide was adequate preincubation experiments were done as well.
The protocol for these experiments consisted of 5 to 10 minutes of preincubation in High
K+ bath solution plus 340pM diazoxide and 5mM sodium azide followed by 10 minutes of
current-voltage measurements recorded at 60 second intervals in the same bath solution.
As for the experiments described above, each trial consisted of 20ms test pulses starting at lOOmV increasing in 20mV increments up to +40mV or +100mV.

Solutions and Chemicals
Ca2+-plus ND96 Solution: 96mM NaCl, 2mM KC1, 1.8mM CaCl2, ImM MgCl2, 5mM Hepes
Ca2+-free ND96 Solution: 82.5mM NaCl, 2mM KC1, 1.8mM MgCb, 5mM Hepes
Standard (ND96) Bath Solution: 96mM NaCl, 2mM KC1, 1.8mM CaCl2, ImM MgCl2, 5mM Hepes
High K+ Bath Solution: 90mM KC1, ImM MgCl2, 1.8mM CaCl2, 5mM Hepes
0 K+ Bath Solution: 105mM NaCl, ImM CaCl2, ImM MgCl2, 5mM Hepes
0.01 K+ Bath Solution: Prepared by addition of 0.33pl of 3M KC1 per 100ml of 0 K+ Bath Solution
0.1 K+ Bath Solution: 105mM NaCl, 0.ImM KC1, ImM CaCl2, ImM MgCl2, 5mM Hepes
0.5 K+ Bath Solution: 105mM NaCl, 0.5mM KC1, ImM CaCl2, ImM MgCl2, 5mM Hepes
Pipette Solution: 3M KC1
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LB plates were made from lOg Bacto-Tryptone, 5g yeast extract, 5g NaCl, 2ml of 2N NaOH, 15g
Bacto-Agar, and nano-H20 to 1000 ml.

This mixture was autoclaved and cooled to approximately 40°C

prior to the addition of ampicillin (lOOpg/ml) and then poured into plates.

LB buffer was made from lOg

Bacto-Tryptone, 5g yeast extract, 5g NaCl, 1ml of 1M MgS04, 10 ml of 1M Tris. and nano-H20 to 1000
ml.

This mixture was autoclaved prior to storage at 4°C.

Ampicillin stock (lOOmg/ml) was made in

sterile RNase-free dH20 and stored at -20°C until needed for LB-ampicillin plates or for bacterial growups.
Glibenclamide (sulfonylurea) was dissolved in a 2:1 (vol.) ethanokdimethyl sulfoxide (DMSO) mixture
to make a 0.001M or 0.1M stock solution. The stock solution was stored at 4°C.

A lOOnM, lOOpM, or

0.5mM working solution was made as needed for experiments; any remaining working solution was
discarded after the second day of experiments. Glibenclamide was obtained from Sigma.
Barium chloride was dissolved in 0 K+ bath solution to make a 0.1M stock solution .

The stock

solution was stored at 4°C. A 2mM or 5mM working solution was made as needed for experiments; any
remaining working solution was discarded after two weeks of experiments.

Barium chloride was obtained

from Sigma.
Diazoxide was dissolved in standard bath solution to make a 68mM stock solution .
solution was stored at 4°C.

The stock

A 340pM working solution (Gribble et ah, 1997) was made as needed for

experiments; any remaining working solution was discarded at the end of each day.

Diazoxide was obtained

from Sigma.
Sodium azide was dissolved in standard bath solution to make a 3M stock solution .

The stock

solution was stored at 4°C. A 3mM or 5mM working solution was made as needed for experiments; any
remaining working solution was discarded at the end of each day. Sodium azide was obtained from Sigma.
The pH of each solution was adjusted to 7.4 with the exception of the diazoxide and sodium azide
solution which was adjusted to a range of 7.4 to 7.6 as the diazoxide is insoluble in water but soluble in
alkaline solutions.
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3-5.

Criteria for Inclusion of ROMK Injected Oocytes in Data Analysis Set
Oocytes were evaluated for level of channel expression. If initial baseline currents

were less than 500nA, the experiment was excluded for poor expression.

An exception

was made for oocytes injected with 0.03pg/pl of mRNA; current readings of less than
500nA were accepted because of the low mRNA concentration.

Only oocytes which

maintained a stable baseline during the first 5 to 7 minutes in control bath solution were
included in our study. A stable baseline was defined as a variation in current measurements
of less than 10 percent for the entire 5 to 7 minute period.

If the oocyte met the above

criteria, an average baseline current was calculated over a 2 minute interval.

To assess

KATP sensitivity, an average current was also calculated over a 2 minute interval for an
end-glibenclamide current reading. The percent inhibition by glibenclamide was calculated
from the change in current ( IMbaseline-Iend_glibencam]de)

over total current.

Total potassium

current was calculated from glibenclamide-sensitive and barium-sensitive currents.

3-6.

Statistical Analysis
To determine the statistical significance of observed differences in the glibenclamide

sensitivity of the ROMK channels when expressed alone or in the presence of an ABC
transporter, we employed both the student t-test and the Kruskal-Wallis one way analysis
of variance on ranks (ANOVA). The student t-test was employed when comparing two
experimental groups. The ANOVA was employed when comparing among greater than
two experimental groups.
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4.

4-1.

Results

ROMK Injected Oocytes

4-1.1. ROMK2-Coinjected Oocytes
We postulate that direct interactions between KATP channels and ABC transporters
are the mechanism by which ABC transporters serve as regulators of channel activity.
Therefore, changes in the structure of either the channel protein or the ABC transporter
would be expected to impact upon their ability to couple and upon channel activity.
Previously we have identified that an intact first nucleotide-binding fold (NBF) is necessary
for the interaction between CFTR and ROMK2 (Kiri.lb).

If, in fact, it is true that these

protein-protein interactions are dependent upon a domain common to all ABC transporters,
such as the NBF, then wild-type SUR1 with intact NBFs should be able to couple with
ROMK2 (Kiri.lb) and confer sulfonylurea sensitivity. To examine this hypothesis, we
conducted two-electrode voltage clamp experiments on Xenopus oocytes injected with
ROMK2 (Kiri.lb) alone, ROMK2 (Kirl.lb)-CFTR, and ROMO (Kirl.lb)-SURl to
assess sulfonylurea sensitivity of the KATP channel alone and in the presence of an ABC
transporter. Resting baseline currents were measured during the 5 to 7 minute equilibration
period in control 0.01K+ bath solution. The final experimental protocol consisted of this
equilibration period followed by a 14 to 15 minute exposure to 500pM glibenclamide, a 2
to 3 minute exposure to 2mM barium chloride to assess total potassium current, and a final
5 minute recovery period in control bath solution.

For some of the ROMK2 (Kirl.lb)-

SUR1 injected oocytes (n=3), an alternate protocol was used initially.

In this protocol,

oocytes had a 5 minute equilibration period in a control 0.1 K+ bath, a 7 minute exposure to
lOOpM glibenclamide, a 5 minute wash in control bath, a 2 minute exposure to 2mM
barium chloride, and finally a 5 minute recovery in control bath. These initial experiments
demonstrated that the effects of glibenclamide inhibition continued into the wash period.
As a result the protocol was modified; the glibenclamide concentration was increased, the
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time of exposure to glibenclamide was increased, and the post-glibenclamide wash period
was eliminated.
Table 3 and Figure 7 summarize the data from oocytes injected with ROMK2
(Kiri.lb) alone, ROMK2 (Kiri.lb)-CFTR and ROMK2 (Kirl.lb)-SURl. The potassium
currents observed in oocytes injected with ROMK2 (Kiri.lb) alone (n=ll) decreased by
23.1 ±6.1% inhibition after exposure to glibenclamide. In contrast, the similar currents in
oocytes expressing ROMK2 (Kiri.lb) with either ABC transporter showed significantly
increased glibenclamide sensitivity (p=0.01).

Coexpression of ROMK2 (Kiri.lb)-CFTR

(n=l 1) and ROMK2 (Kirl.lb)-SURl (n= 13) resulted in 54.8± 10.8% and 56.5±6.7%
decrease in potassium current in the presence of glibenclamide inhibition, respectively.
This data supports the hypothesis that both of these ABC transporters with intact NBFs
were able to interact with ROMK2 (Kir 1.1b) resulting in an enhanced sensitivity to
glibenclamide.

In addition, the difference in glibenclamide inhibition between ROMK2

(Kirl.lb)-CFTR and ROMK2 (Kiri,lb)-SURl was not found to be statistically significant
(p=0.89).
Figure 8 depicts a representative time-course for an experiment in an oocyte
expressing ROMK2 (Kirl.lb)-SURl as well as individual current-voltage traces at time
points throughout the experiment.

4-1.2. ROMK1-Coinjected Oocytes
Having determined that the NBF1 of ABC transporters is involved in proteinprotein interactions with ROMK2 (Kiri.lb), we directed our attention to the “associated”
Katp channel itself.

To examine if there are domains within the KATP channel itself

important for coupling to occur, we studied N-terminus modifications in ROMK.

Two-

electrode voltage clamp experiments were conducted on Xenopus oocytes injected with
ROMK1 (Kiri.la) alone, ROMK1 (Kirl.la)-CFTR, and ROMK1 (Kirl.la)-SURl to
determine if there was any change in sulfonylurea sensitivity when the KATP channel was
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expressed alone versus in the presence of an ABC transporter.

The protocol for these

oocytes was as described above. Again, the alternate protocol was used initially for a few
of the ROMK1-SUR1 coinjected oocytes (n=2).
Table 3 and Figure 9 summarize the data from oocytes injected with ROMK1
(Kiri.la) alone, ROMK1 (Kirl.la)-CFTR and ROMK1 (Kirl.la)-SURl.

Oocytes

injected with ROMK1 (Kir 1.1 a) alone (n=8) demonstrated mild to moderate inhibition
(28±2.8%) of potassium currents after exposure to glibenclamide. Oocytes injected with
ROMK1 (Kirl.la)-SURl (n=6) demonstrated a similar degree of glibenclamide inhibition
(24.6±6.3%, p=0.6) suggesting that coexpression of these two subunits did not result in
an interaction capable of altering the sulfonylurea sensitivity.

These findings can be

contrasted to those from oocytes coexpressing ROMK2 (KiiT.lb)-SURl where there is an
enhanced sulfonylurea sensitivity.

Interestingly, in oocytes injected with ROMK1

(Kirl.la)-CFTR (n=6) the currents were significantly less sensitive to glibenclamide, with
only of 6±0.02% (p=0.009) inhibition of the total potassium current when compared to
either ROMK1 (Kiri, la) alone or ROMK1 (Kirl.la)-SURl potassium currents.

4-2.

BIR Injected Oocytes
To examine the normal coupling interactions of SUR1 and BIR (Kir6.2) and the

effects of mutations in the M2 region of the channel pore upon this interaction, experiments
were performed on oocytes expressing BIR (Kir6.2)-SUR1, A9 (a BIR/Kir6.2 mutant)SUR1, as well as SUR1 and BIR (Kir6.2) alone.

4-2.1. Expression of BIR and SUR1 Alone
BIR (Kir6.2) is postulated to be the pore subunit of the pancreatic beta cell KATP
channel. Two-electrode voltage clamp experiments were initially performed on Xenopus
oocytes injected with BIR (Kir6.2) alone (n=3/5) to determine if this subunit resulted in
channel activity.

These oocytes were placed in bath solutions with varying potassium
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concentrations and channel activity was measured.

Current recordings were made in

standard ND96 (2mM KC1) bath solution then High K+ (90mM KC1) bath solution. When
placed in the High K+ bath, oocytes demonstrated a slight increase in potassium current as
would be expected from the greater electrochemical potassium gradient.

However, this

change in potassium current was similar to those measured in uninjected oocytes (n=8) or
H20-injected oocytes (n=5).

These results suggested that the BIR (Kir6.2) subunit

expressed alone did not result in a functional potassium channel.
Next we turned our attention to SUR1 which is postulated to be the regulatory
subunit and ATP sensor of the pancreatic beta cell KATP channel. We repeated the above
protocol in oocytes expressing SUR1 alone (n=5) to confirm that SUR1 was not a
potassium channel itself and to determine if SUR1 would couple with an endogenous Kjr
channel.

Potassium currents were found to be similar to those measured in uninjected

oocytes in these experiments as well. As a member of the ABC transporter superfamily,
SUR1 possesses two NBFs allowing it to be responsive to changes in intracellular ATP
concentrations. To assess if sodium azide metabolic inhibition of the oocyte would cause
channel activation, experiments were done exposing the SUR1-injected oocytes (n=3) to
High K+ bath solution for 5 minutes then to 3mM sodium azide for 15 minutes.

Under

these experimental conditions, oocytes injected with SUR1 alone did not demonstrate an
appreciable increase in potassium currents.
The result of our experiments in oocytes expressing BIR (Kir6.2) or SUR1 alone
confirmed those reported by Gribble et al. demonstrating that coexpression of both
subunits was necessary to reconstitute KATP currents.

4-2.2. Coexpression of BIR and SUR1
To assess the normal coupling of both KATP channel subunits, we examined oocytes
coexpressing BIR (Kir6.2)-SUR1.

In these experiments we exposed the coinjected

oocytes to a High K+ solution followed by a High K+ solution plus 340pM diazoxide and
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5mM sodium azide.

Treatment with diazoxide and sodium azide resulted in potassium

currents significantly greater than measured in High K+ solution alone. We were able to
demonstrate this in 2 oocytes confirming the results reported by Gribble et al. However,
we experienced some difficulty in repeating this result consistently. Whether this reflects
problems with the Xenopus oocyte as a reliable expression system or is an issue with the
quality of the mRNA has not been determined. In the oocytes that did express, however,
the average currents measured at -lOOmV were approximately -8 to -40pA which are
similar to those previously reported (Gribble et al., 1997).

4-2.3. Coexpression of a BIR mutant and SUR1
Having confirmed that the Xenopus oocyte expression system was adequate for
studying interactions between BIR (Kir6.2) and SUR1 we examined oocytes coinjected
with a BIR/Kir6.2 mutant (A9) and SUR1.

Our goal was to determine if potassium

currents could be stimulated in these oocytes. Oocytes were equilibrated for 3 minutes in
High K+ bath solution then exposed to High K+ bath solution plus 340pM diazoxide and
5mM sodium azide for 15 minutes. No change in potassium current was observed (n=2).
To assess if duration of exposure to diazoxide and sodium azide was adequate,
preincubation experiments were done as well.

The protocol for these experiments

consisted of 5 to 10 minutes of preincubation in High K+ bath solution plus 340pM
diazoxide and 5mM sodium azide followed by 10 minutes of current-voltage measurements
recorded at 60 second intervals in the same bath solution. Again, no change in potassium
current was observed (n=5).

These preliminary findings

appear to suggest that

coexpression of the BIR (Kir6.2) mutant A9 with SUR1 does not result in a functional
Katp channel and that altering the M2 region of the channel pore leads to a dysfunctional
channel.
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5.

5-1.

Discussion

Effects of Mutations in CFTR upon Interactions with ROMK2
A recent study by McNicholas et al. suggested that mutations in specific domains of

CFTR—the first nucleotide-binding fold (NBF1)—interfere with CFTR’s ability to interact
with the ROMK2 (Kiri. lb) channel (McNicholas et al., 1997). In that study glibenclamide
was shown to inhibit 56% of potassium current in oocytes expressing both ROMK2
(Kiri.lb) and CFTR. In contrast, there was only 11% inhibition of potassium currents in
oocytes expressing ROMK2 (Kiri.lb) alone. Furthermore, when ROMK2 (Kir 1.1b) was
expressed with CFTR constructs containing mutations in the first nucleotide-binding fold
(NBF1), there was no enhancement of glibenclamide sensitivity suggesting that an intact
NBF1 is necessary for this interaction. Supporting this hypothesis, oocytes injected with
ROMK2 (Kiri.lb) and a truncated CFTR construct containing an intact NBF1

still

exhibited enhanced (46%) glibenclamide sensitivity. In contrast, when ROMK2 (Kir 1.1b)
was coexpressed with a truncated CFTR construct lacking NBF1 only 12% inhibition
remained. Given that NBFs are motifs common to ABC transporters these data suggest
that certain family members may be able to substitutes for other members.

5-2.

Ability of SlJRl to Substitute for CFTR in Interactions with ROMK2
Pursuing this theory further, we wondered if SURl could substitute in the ROMK2

(Kirl.lb)-CFTR interaction.

Studying SURl’s ability to substitute for CFTR in its

interactions with the ROMK family of channel proteins offered the opportunity to examine
similarities and differences in the domain organization of these two ABC transporters
(Figure 10).

In our studies, oocytes coexpressing either ROMK2 (Kiri.lb)-CFTR or

ROMK2 (Kirl.lb)-SURl

demonstrated enhanced sensitivity to sulfonylureas when

compare to ROMK2 (Kiri.lb) alone. In addition, when compared between themselves,
the degree to which these two ABC transporters were able to enhance glibenclamide
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sensitivity was not statistically significant. These data not only demonstrate that it may be
possible for one family member to substitute for another and provide similar regulatory
function but also suggest that similarities exist in how CFTR and SUR1 interact with
ROMK2 (Kiri.lb). Furthermore, it implicates the NBF as an essential component for this
interaction. As the NBF is the region of the protein that binds ATP, one can speculate that
this interaction may be altered by energy dependent processes such as phosphorylationdephosphorylation. Additional studies focusing upon these questions will need to be done.

5-3.

Effects of Alterations in ROMK upon Interactions with CFTR
Clearly changes in the ABC transporter impact upon its ability to interact with

heterologous channel proteins.

If, as we postulated, the relationship between ABC

transporters and channels are dynamic involving direct protein-protein interactions, we
would expect that changes in the channel itself would also effect these interactions.
Specifically, we postulated that changes in the cytoplasmic N-terminus of ROMK would
alter its interaction with CFTR.

Our choice to study the N-terminus was based upon

studies by Tinker et al. and Tucker et al.

Tinker et al. suggested that assembly of a

functional multimeric Kir channel is dependent upon compatibility of the proximal Cterminus and the M2 region (Tinker et al., 1997).

Tucker et al. demonstrated that BIR

(Kir6.2) mutants with C-terminus deletions expressed channel activity when injected alone
into Xenopus oocytes while those with N-terminus deletions did not express channel
activity, suggesting that the C-terminus may inhibit channel activity by blocking the pore
(Tucker et al., 1997).

When the C-terminus truncated forms of BIR (Kir6.2) were

coexpressed with SUR1, Tucker et al. found enhancement of ATP sensitivity as well as
restoration of the effects of diazoxide, tolbutamide, and Mg-ADP, suggesting that SUR1
coupling is not affected by the C-terminus deletions.

In addition, studies (Tinker et al.,

1997) have shown the N-terminus and Ml region to be important in the assembly of
functional multimeric voltage-gated potassium channels, suggesting that the N-terminus is
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capable of playing a role in protein-protein interactions. Our studies, as described earlier,
had confirmed that a ROMK2 (Kirl.lb)-CFTR interaction exists.

To examine if

alterations in the N-terminus of ROMK2 (Kiri.lb) would impact upon CFTR’s ability to
increase inhibition of ROMK2 (Kiri.lb) by glibenclamide, we studied another isoform of
the ROMK channel, ROMK1 (Kir 1.1 a) whose N-terminus had an additional 19 amino
acids (Figure 11).

Both isoforms, ROMK1 (Kiri.la) and ROMK2 (Kiri.lb), express

functional Kir channels when expressed alone. We found that oocytes expressing ROMK1
(Kirl.la)-CFTR did not exhibit the enhanced glibenclamide sensitivity we had seen in
oocytes expressing ROMK2 (Kiri.lb)-CFTR.

In fact, there was a statistically significant

decrease in glibenclamide inhibition of the potassium current as compared to oocytes with
ROMK1 (Kiri.la) alone, suggesting that there was an antagonistic effect on glibenclamide
sensitivity. There are a number of possible explanations for the decrease in sensitivity.
One possible explanation is that there was no coupling between CFTR and ROMK1
(Kiri.la) and that the decreased effect of glibenclamide, although statistically significant, is
not physiologically relevant. Another explanation may be that some coupling of the two
subunits occurs which interferes with sulfonylurea inhibition of channel activity. Further
studies will need to be done to address this issue.

However, these data suggest that

alterations in the N-terminus of the Kir channel subunit also effect the ABC transporterchannel protein interaction.

5-4.

Effects of Alterations in ROMK upon Interactions with SUR1
To assess if the ROMK1 (Kirl.la)-CFTR findings describe a real interaction with

inhibitory effects upon glibenclamide sensitivity or reflect a lack of coupling between the
two subunits, we examined another ABC transporter, SURl.

In oocytes coexpressing

ROMK1 (Kirl.la)-SURl, there was neither increase nor decrease of glibenclamide
inhibition compared to ROMK1 (Kir 1.1 a) alone suggesting that no interaction occurred.
The simplest explanation of this finding is that the results observed with ROMK1
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(Kirl.la)-CFTR represent a non-interactive state as well and that statistical significance
was a function of the statistical analysis.
If one examines ROMK1 (Kiri.la) versus ROMK2 (Kiri, lb), the 19 amino acid
difference is in an region that has been shown to have a number of PKC sites. Thus, the
alteration in the interaction may be dependent on a number of factors: changes in PKC
activity, specifically the phosphorylation or dephosphorylation states of the channel, and/or
conformational changes. Further studies will need to be done.

5-5.

Effect of a Mutation in BIR upon Interactions with SUR1
Previous studies have shown that mutations within the SUR1 subunit have resulted

in cases of PHHI, presumably through decreased KATP channel activity and subsequent
oversecretion of insulin (Thomas et al., 1995; Aguilar-Bryan and Bryan, 1996; Kane et al.,
1996; Thomas et al., 1996; Dunne et al., 1997).

Specifically, mutations in NBF2 and

NBF1 have been implicated. As SUR1 with its NBFs is believed to be responsible for
sensing ATP levels within the pancreatic beta cell, mutations affecting the interaction
between the NBF and ATP could result in the clinical features of PHHI.

BIR (Kir6.2) is

believed to be the predominant pore-forming subunit of the pancreatic beta cell KATP
channel. However, BIR (Kir6.2) expressed alone within the Xenopus oocyte expression
system does not produce KATP channel currents and appears to be inactive. A recent study
by Thomas et al. reported a mutation in BIR (Kir6.2) which is predicted to disrupt the
second transmembrane domain of the KIR channel.

This mutation was found in a child

affected with PHHI, with clinical features that did not appear to differ from cases where the
mutation was found to be present in SURF

In our study we examined yet another BIR

(Kir6.2) mutant, A9, which is postulated to produce a mutation of the M2 region of BIR
(Kir6.2).
In our study we were able to replicate in the Xenopus oocyte expression system
some of the results reported in 1997 by Gribble et al. Expression of either BIR (Kir6.2) or
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SUR1 alone did not reconstitute KATP currents. In two oocytes coexpressing B1R (Kir6.2)
and SUR1 we were able to demonstrate reconstitution of this current when stimulated with
diazoxide and sodium azide. When oocytes coexpressing the BIR (Kir6.2) mutant A9 and
SUR1 were measured, current readings were similar to those of uninjected or H,0-injected
oocytes. This suggested that the interaction between the BIR (Kir6.2) and SUR1 subunits
was somehow disrupted as a result of the mutation in A9.
As the interaction between SUR1 and BIR (Kir6.2) is still unclear there are a
number of mechanisms by which this disruption could occur.

Our hypothesis was that

direct interactions are responsible for SURl’s regulation of BIR (Kir6.2) and that
mutations affecting the ability of the two subunits to interact would result in KATP
dysfunction and the presentation of PHHI.

It is also possible that the A9 mutation alters

the processing of the Kir subunit making it less available to interact with SUR1.
stoichiometry of the relationship between SUR1

and BIR (Kir6.2)

in

Since the
order for

reconstitution of a function KATP channel also has not been elucidated this is an area that
needs further investigation.
Alternatively, a recent study by Shyng et al. examined the effect of mutations of
pore-lining residues upon stability of the open channel and suggested that structural
changes within the BIR (Kir6.2) subunit may impact upon ATP-sensitivity of the channel
(Shyng et al., 1997). Another mechanism by which mutations in BIR (Kir6.2) may result
in an inactive KATP channel is through alterations in either the conformation or structure of
the pore-lining residues.

5-6.

Clinical Implications
As defects in ion channels and transporters are responsible for numerous human

diseases, elucidation of their role in pathophysiology constitutes the first step in improving
clinical management and developing therapeutic interventions.

The ABC transporter

superfamily of proteins has been implicated in a wide range of human diseases (Table 1),
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such as CF and PHHI. Consequently, determination of the structure-function relationship
of ABC transporters with regard to their intrinsic channel/transporter activity as well as
their regulation of heterologous channels may provide insights into disease process which
can be translated into alternative targets for therapy. Of particular interest is the ability of
some ABC transporters to substitute for other members of the superfamily and perhaps to
couple with multiple ion channels.

Our initial studies suggest that this is due to the

presence of specific motifs of ABC transporters, such as the NBFs.

Mutations in the

NBFs in CFTR and SUR1 have been associated with clinical CF and PHHL
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Figure 1. The Typical ABC Transporter. This is a schematic representation of a
typical ABC transporter with its four core domains. The two nucleotide-binding domains
are represented by the cross-hatched areas. The transmembrane domains are depicted here
with six alpha-helical segments with the N- and C-termini on the cytoplasmic face.
Although these domains are pictured as separate polypeptides here, they may also be fused
to form a multidomain protein. The * designates the cytoplasmic loop which contains a
short sequence motif conserved between many ABC transporters. Adapted from Higgins,
1992.
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Figure 2. Mechanisms of Channel Regulation.
1. The substrate (X) transported by the ABC transporter acts to modulate channel activity
in an autocrine fashion.
2. The ABC transporter acts directly upon the channel protein.
3. The ABC transporter facilitates increased insertion of the channel protein into the
membrane.
4. The ABC transporter regulates the channel protein via an intermediate protein molecule.
Adapted from Higgins, 1995.
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Figure 3. Model of the Cystic Fibrosis Transmembrane Conductance
Regulator. This schematic illustration shows the atypical five domain structure of CFTR
containing not only two transmembrane domains and two nucleotide-binding domains, but
also as additional regulatory (R) domain.
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Figure 4. Ion Channels Involved in Regulation of Respiratory Airway
Secretions. Chloride enters the cell across the basolateral membrane coupled to sodium
movement out of the cell. This cotransport process may involve either a Na7Cf
cotransporter or a Na7K72Cl" cotransporter. The chloride then moves out of the cell
through chloride channels on the apical membrane. This net movement of chloride is
driven by the presence of the basolateral Na7K+ pump, the basolateral potassium channel,
and the apical sodium channel.
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Figure 5. Proposed Model of the Pancreatic Beta Cell KATP Channel. The
pancreatic beta cell KATP channel is postulated to be a complex of SUR1 and BIR (Kir6.2).
Although we represent this relationship as one to one, the actual stoichiometry of this
complex is unknown.
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Figure 6. Glucose Homeostasis and Insulin Secretion. This figure illustrates the
pathway for insulin secretion in the pancreatic beta cell. The pancreatic KATP channel
(represented here as the SUR1 and BIR/Kir6.2 complex) maintains the resting membrane
potential for the cell. An increase in the glucose concentration results in closure of the KATP
channel. Depolarization of the cell activates the voltage-dependent calcium channels. The
influx of calcium ions triggers exocytosis and insulin release. Sulfonylureas function by
blocking the KATP channel and causing depolarization of the cell membrane.
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Figure 7. Glibenclamide Sensitivity of ROMK2 Currents. This figure is a
summary of the data obtained for ROMK2 expressed alone, or with CFTR or SUR1 as
indicated on the X-axis.
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Figure 8. Time-Course and Individual Current-Voltage Traces. This is a
representative time-course for an experiment in oocytes injected with ROMK2-SUR1. The
individual current-voltage traces were taken at various points throughout the experiment.
The protocol was as follows: 5 minutes control —» 13 minutes in glibenclamide —» 3
minutes in barium chloride —>• 5 minutes wash.
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Glibencamide sensitivity of ROMK1 currents

Figure 9. Glibenclamide Sensitivity of ROMK1 Currents. This figure is a
summary of the data obtained for ROMK1 expressed alone, or with CFTR or SUR1 as
indicated on the X-axis.
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Figure 10. Comparison of Structure of CFTR and SURL Although CFTR and
SUR1 are both members of the ABC transporter superfamily, each is a somewhat atypical
example. Of note, CFTR has an additional regulatory (R) domain. SUR1 has a nine
alpha-helical N-terminus transmembrane domain and a four alpha-helical C-terminus
transmembrane domain. In addition, SURl’s N-terminus is extracellular while most ABC
transporters, including CFTR, have a cytoplasmic N-terminus.
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Figure 11. Isoforms of the ROMK Renal KATP Channel. This figure illustrates
the general structure of the Kir family of potassium channels to which the ROMK channel
belongs. ROMK1 (Kiri.la) and ROMK2 (Kir 1.1b) are two isoforms that differ in their
N-terminus by 19 amino acids but are otherwise identical. The amino acid sequence of
their N-termini are aligned above.
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ABC Transporter

Association with Human Disease

ABCR

Stargardt macular dystrophy1

ALD

adrenoleukodystrophy2

CDR1

drug resistant candidosis3

CFTR

cystic fibrosis3'4

EhPgpl

drug resistant amoebiasis3

IdMDR

drug resistant visceral leishmaniasis3

pfMDR2

drug resistant malaria3

P-glycoprotein (MDR1)

multidrug resistance (cancer chemotherapy)5

PMP70

Zellweger syndrome6

SMDR2

drug resistant schistosomiasis3

SUR1

persistent hyperinsulinemic hypoglycemia of infancy7'8, non-insulin
dependent diabetes mellitus9

TAPI

Behcet’s disease10, multiple sclerosis"

TAP2

bare lymphocyte syndrome type l3, multiple sclerosis"

VgA

drug resistant wound infections, pneumonia, impetigo3

Table 1. ABC Transporters and Associated Diseases. These are some examples
of human diseases associated with ABC transporters.
'Allikmets et al., 1997; 2Mosser et al., 1993; 3Decottignies and Goffeau, 1997; 4Riordan et al., 1989; 5Gill
et al., 1992; 6Gartner et al., 1992; 7Bryan and Aguilar-Bryan, 1996; 8Thomas et al., 1995; yInoue et al.,
1996; "'Gonzalez-Escribano et al, 1995; "Middleton et al, 1994.
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Class of Defect

Examples

Domain

I. Protein production

G542X

NBD1

3905 insT

NBD2

621 + G^T

TMD1

AF508

NBD1

AI507

NBD1

S549I

NBD1

S549R

NBD1

A559T

NBD1

N1303K

NBD2

G551D

NBD1

G551S

NBD1

G1224E

NBD2

S1255P

NBD2

G1349D

NBD2

R117H

TMD1

R334W

TMD1

R347P

TMD1

II. Protein processing/trafficking

III. Channel regulation/activation

IV. Chloride conductance

Table 2. Classes of CFTR Mutations That Result in Cystic Fibrosis. CFTR
mutations can be separated into four classes of defects. Some examples of these mutations
and what domain they effect are listed above. NBD=nucleotide-binding domain,
TMD=transmembrane domain. Adapted from Welsh, et ah, 1993.
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Summary of Data in ROMK Injected Oocytes

ROMK2 Injected Oocytes

Construct

% Inhibition

P=

n=

ROMK2

23.1 ±6.1

—

11

ROMK2-CFTR

54.8±10.8

0.02

11

ROMK2-SUR1

56.5±6.7

0.001

13

ROMK1 Injected Oocytes

Construct

% Inhibition

P=

n=

ROMK1

28±2.8

—

8

ROMK1-CFTR

6±0.02

0.00006

6

ROMK1-SUR1

14.6±6.3

0.6

6

Table 3. Summary of Data in ROMK Injected Oocytes. The percent inhibition
is expressed as mean±SE. P values are based upon Student t-test. Comparison was made
to ROMK2 or ROMK1 alone, as appropriate.
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